Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAB001 in Early-stage Glucocorticoid-induced Osteonecrosis of the Femoral Head
NCT07471880Phase 2Active, not recruiting
- Sponsor
- Zhongshan Laibo Ruichen Biopharmaceutical
- Start
- Dec 2024
- Primary completion
- Oct 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of LLP2A-alendronate in osteonecrosis of the femoral head (ONFH), sponsored by Zhongshan Laibo Ruichen Biopharmaceutical. Started Dec 2024; status: active, not recruiting.
02
Drugs
LLP2A-alendronate
03
Conditions
osteonecrosis of the femoral head (ONFH)
Beyond the preview
Go deeper on NCT07471880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07471880.